Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Tool Accurately Determines Breast Cancer Prognosis

By LabMedica International staff writers
Posted on 18 Jul 2025

A new study has found that cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to treatment. More...

The research, published in the journal Patterns, marks a significant step toward developing artificial intelligence (AI) tools to help oncologists more accurately determine prognoses and decide which treatments may be most effective on a case-by-case basis.

Researchers at Johns Hopkins University (Baltimore, MD, USA) have designed an interpretable machine learning model that analyzed images of microscopic tissues and biopsy samples from 579 breast cancer patients who were undergoing standard treatments such as chemotherapy. The model examined both the tumor and the surrounding tissue, assessing every cell’s position in relation to the tumor and interactions with neighboring cells. This allowed the algorithm to detect 66 unique cell patterns and categorize patients into seven prognostic groups based on these patterns. Unlike conventional AI methods, the model could clearly identify which specific elements contributed to each pattern, allowing researchers to reverse-engineer the data and uncover the driving factors behind the groupings.

The model’s validation revealed several significant findings. One group of patients with the best survival outcomes had a distinct combination of three cell types: CK8-18high, CXCL12high, and CK+CXCL12+. On the other hand, patients with self-aggregated HER2+ tumor cells had the worst outcomes—a result that aligns with the known aggressiveness of HER2-positive breast cancers. Additionally, triple-negative breast cancer patients with well-organized immune cells surrounding their tumors also had better prognoses than others with the same condition. These results suggest that analyzing spatial tissue patterns may provide oncologists with valuable biomarkers for predicting patient outcomes and personalizing treatment strategies. Moving forward, the researchers plan to expand their methodology to other imaging technologies and apply it to different types of cancer to uncover more actionable insights.

"We're developing a toolbox that you can use anytime you have a massive data set and you don't want to start with an explicit hypothesis," said first author Zhenzhen Wang, a PhD candidate in biomedical engineering at Johns Hopkins University. "Typically, you'd have to design a study to ask if one specific pattern of cells is important, and check if the answer is yes or no. But with our model, we can save time by asking open-ended questions about which patterns are important when trying to understand how patients will respond to treatment or have a better chance of survival."

Related Links:
Johns Hopkins University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.